Alerts the Risk of B6 Deficiency Using Carbidopa/levodopa
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.5 Articles
5 Articles
Agency determines updating of the Carbidol bull and recommends monitoring of vitamin levels before and during treatment; decision was motivated by cases of seizures identified by the FDA in the United States The National Health Surveillance Agency (Anvisa) issued an alert on the risk of vitamin B6 deficiency in patients who use medicines [...]
Tribuna Online
The National Agency for Health Surveillance (Anvisa) has issued alerts on the risk of vitamin B6 deficiency in patients who use medicinal products containing carbidopa/levodopa, indicated for the treatment of Parkinson's disease. Deficiency, according to the agency, may be associated with seizures.In a note, Anvisa reported that the decision was made after the United States Food and Drug Administration (FDA), a drug regulatory agency, identified…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
